These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7840571)

  • 1. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.
    Di Modugno E; Erbetti I; Ferrari L; Galassi G; Hammond SM; Xerri L
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2362-8. PubMed ID: 7840571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of the tricyclic beta-lactam GV104326.
    Wise R; Andrews JM; Brenwald N
    Antimicrob Agents Chemother; 1996 May; 40(5):1248-53. PubMed ID: 8723475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
    Di Modugno E; Broggio R; Erbetti I; Lowther J
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
    Behra-Miellet J; Dubreuil L; Calvet L
    Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
    Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
    J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of clinical isolates from German hospitals to amoxicillin/clavulanic acid (Augmentin) compared with other antibiotics.
    Focht J; Klietmann W; Nösner K; Rolinson GN; Johnsen J
    Chemotherapy; 1988; 34(4):332-40. PubMed ID: 3264780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall.
    Fontana R; Altamura M; Arcamone F; Mazzariol A; Morandotti G; Sperning R; Cornaglia G
    J Antimicrob Chemother; 1998 May; 41(5):513-25. PubMed ID: 9630405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro antibacterial activity of meropenem, a new carbapenem: European data].
    Debbia EA; Marchese A; Pesce A; Schito GC
    New Microbiol; 1995 Oct; 18 Suppl():1S-17S. PubMed ID: 8574928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
    Bauernfeind A; Jungwirth R; Schweighart S
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
    Ednie L; Shapiro S; Appelbaum PC
    Diagn Microbiol Infect Dis; 2007 May; 58(1):133-6. PubMed ID: 17240107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.